Page last updated: 2024-08-26

fulvestrant and paclitaxel

fulvestrant has been researched along with paclitaxel in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (22.73)	29.6817
2010's	10 (45.45)	24.3611
2020's	7 (31.82)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J	1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E	1
Beckman, BS; Burow, ME; McLachlan, JA; Tang, Y; Weldon, CB	1
Perez, EA; Roy, V	1
Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J	1
Davidson, NE; Fan, W; Huang, Y; Park, BH; Sui, M	1
Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N	1
Chang, J; Fan, W; Sui, M	1
Coser, KR; McSweeney, KR; Rivizzigno, D; Shioda, K; Shioda, T; Yeh, WL	1
Fan, W; Han, N; Huang, Y; Jiang, D; Wang, S; Xu, L; Xu, M; Zhou, L	1
Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM	1
Chun, HY; Jung, YS; Park, BJ; Yoon, MH	1
Do, IG; Jang, J; Kang, WK; Kim, KM; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH	1
Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S	1
Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F	1
Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A	1
Braiteh, FS; Hamilton, E; Huang, M; Liaw, DCH; Pant, S; Strauss, JF; Ulahannan, SV	1
Beaufort, CM; Bos, MK; Boven, E; de Jonge, E; Helmijr, JCA; Jager, A; Jansen, MPHM; Lam, SW; Martens, JWM; Motta, G; Sleijfer, S	1
Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K	1

Reviews

4 review(s) available for fulvestrant and paclitaxel

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
New therapies in the treatment of breast cancer. Seminars in oncology, 2006, Volume: 33, Issue:3 Suppl 9 Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Paclitaxel; Sirolimus; Vinblastine	2006
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone	2019
"The emerging role of capivasertib in breast cancer". Breast (Edinburgh, Scotland), 2022, Volume: 63 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2	2022

Trials

3 trial(s) available for fulvestrant and paclitaxel

Article	Year
Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific reports, 2014, Dec-23, Volume: 4 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease-Free Survival; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Receptors, Estrogen; Stomach Neoplasms; Survival Rate	2014
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors. Cancer, 2023, 06-15, Volume: 129, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Enzyme Inhibitors; Fulvestrant; Humans; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase	2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer. Breast cancer research and treatment, 2023, Volume: 200, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fulvestrant; Humans; Mutation; Paclitaxel	2023

Other Studies

15 other study(ies) available for fulvestrant and paclitaxel

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13 Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays	2020
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved? European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2	2021
Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. The Journal of steroid biochemistry and molecular biology, 2001, Volume: 78, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, bcl-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Paclitaxel; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2001
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Estradiol; Flow Cytometry; Fulvestrant; Humans; Hydroxyurea; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Paclitaxel; Purines; RNA, Small Interfering; Roscovitine; Spindle Apparatus; Survivin; Thymidine; Transfection	2007
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer research, 2007, Jun-01, Volume: 67, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Microtubules; Mitosis; Paclitaxel; Prohibitins; Transfection	2007
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer science, 2011, Volume: 102, Issue:11 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays	2011
Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors. Breast cancer research and treatment, 2012, Volume: 134, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Paclitaxel; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays	2012
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PloS one, 2013, Volume: 8, Issue:4 Topics: Apoptosis; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; RNA Interference; src-Family Kinases; Tamoxifen	2013
Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy. Cancer letters, 2014, May-01, Volume: 346, Issue:2 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitosis; Paclitaxel; Random Allocation; Receptors, Estrogen; Xenograft Model Antitumor Assays	2014
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer letters, 2014, Aug-01, Volume: 350, Issue:1-2 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53	2014
Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction. Neoplasia (New York, N.Y.), 2014, Volume: 16, Issue:12 Topics: Antineoplastic Agents, Hormonal; Blotting, Western; BRCA1 Protein; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fluorescent Antibody Technique, Indirect; Fulvestrant; Genetic Vectors; Humans; Kidney Neoplasms; Microtubule-Organizing Center; Paclitaxel; Rad51 Recombinase; Transfection; Tubulin; Tubulin Modulators; Von Hippel-Lindau Tumor Suppressor Protein	2014
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women. Applied health economics and health policy, 2022, Volume: 20, Issue:4 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines	2022
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment. Molecules (Basel, Switzerland), 2023, Aug-30, Volume: 28, Issue:17 Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites	2023